Event-Driven Stocks

Century Therapeutics, Inc.

IPSCNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 4 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$109.2M$6.6M$2.2M$5.2M——
Operating income−$17.3M−$138.1M−$146.5M−$133.8M−$94.9M−$53.9M
Net income−$9.6M−$126.6M−$136.7M−$130.9M−$95.8M−$53.6M
Total assets$223.7M$353.2M$360.7M$486.5M$437.4M$106.8M
Total liabilities$64.8M$191.9M$175.9M$183.8M$41.1M$33.4M
Equity$158.9M$161.4M$184.8M$302.7M$396.2M−$106.4M
EPS (diluted)$-0.14$-1.61$-2.30$-2.96$-2.96$-7.16
Shares out.86.0M64.8M59.2M58.8M58.5M7.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−15.8%
Net margin
−8.8%
Return on equity
−6.0%
Return on assets
−4.3%
Return on capital (ROCE)
−8.5%
Liabilities / assets
29.0%
Debt / equity
0.41×
Book value / share
$1.85
Revenue growth (YoY)
1556.8%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-6.53distress
Accruals / assets
42.2%high accruals
Piotroski F-Score
5/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
42
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 0Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 1 severe● 4 warning● 2 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
0 acquisitions11 disposalsnet −139,109 shares · last 11
InsiderDateTypeSharesPrice
Pfeiffenberger BrentOfficer — President and CEOMay 15, 2026Tax withholding31,172$2.34
Carr DouglasOfficer — SVP Finance &amp; OperationsMay 4, 2026Sell264$2.34
Cowan ChadOfficer — Chief Scientific OfficerApr 1, 2026Tax withholding1,365$2.19
Carr DouglasOfficer — SVP Finance &amp; OperationsMar 12, 2026Sell7,043$2.55
Russotti GregoryOfficer — See RemarksMar 12, 2026Sell10,076$2.55
Pfeiffenberger BrentOfficer — President and CEOMar 11, 2026Tax withholding55,397$2.73
Cowan ChadOfficer — Chief Scientific OfficerMar 11, 2026Tax withholding1,431$2.73
Russotti GregoryOfficer — See RemarksMar 9, 2026Sell479$2.54
Carr DouglasOfficer — SVP Finance &amp; OperationsMar 9, 2026Sell247$2.54
Pfeiffenberger BrentOfficer — President and CEOMar 6, 2026Tax withholding463$2.56
Pfeiffenberger BrentOfficer — President and CEOFeb 13, 2026Tax withholding31,172$1.75

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202612.2M18.7+1.4%
Apr 30, 202612.0M13.8+9.9%
Apr 15, 202611.0M8.0+6.6%
Mar 31, 202610.3M5.6+19.3%
Mar 13, 20268.6M6.3+36.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.